H.C. Wainwright raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps a Buy rating on the shares. MannKind’s Q1 results missed estimates but this does not change the core thesis, which is increasingly centered on the durability and upside potential of the company’s royalty and collaboration revenue streams, the analyst tells investors in a research note. The firm cites royalty durability and potential pipeline upside for the target boost.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind reports Q1 EPS (2c), consensus 1c
- MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
- MNKD Earnings this Week: How Will it Perform?
- MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
- MannKind price target lowered to $8 from $10 at Mizuho